Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

Completed · Phase 1

Conditions studied: Hepatitis C Virus

In brief

To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of PF-04878691.

Key facts

Study ID

NCT00810758

Run by

Pfizer

People needed

24

Starts

2009-01-01

Expected to finish

2009-11-01

Last updated by the study team

2009-12-01

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and/or female subjects between the ages of 18-55, inclusive.
• Body Mass Index (BMI) of 18-30 kg/m2; total body weight >50kg (110lbs).

You may not qualify if…

• Pregnant or nursing females.
• Females of child-bearing potential.
• Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, allergic or autoimmune disease or clinical findings at screening.
• Smoking within the previous 6 months.

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.